{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:36:27Z","timestamp":1762004187770},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.ymgme.2009.11.001","type":"journal-article","created":{"date-parts":[[2009,11,18]],"date-time":"2009-11-18T03:14:24Z","timestamp":1258514064000},"page":"367-373","source":"Crossref","is-referenced-by-count":32,"title":["Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative"],"prefix":"10.1016","volume":"99","author":[{"given":"S.","family":"Sirrs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.T.R.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.G.","family":"Bichet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Casey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Lemoine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Flowerdew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.S.","family":"Sinasac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.L.","family":"West","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2009.11.001_bib1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2009.11.001_bib2","first-page":"2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized","volume":"285","author":"Schiffmann","year":"2001","journal-title":"Controlled trial JAMA"},{"key":"10.1016\/j.ymgme.2009.11.001_bib3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alfa-galactosidase A replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.ymgme.2009.11.001_bib4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2009.11.001_bib5","doi-asserted-by":"crossref","first-page":"e598","DOI":"10.1371\/journal.pone.0000598","article-title":"Treatment of Fabry disease: Outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2mg\/kg","volume":"7","author":"Vedder","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymgme.2009.11.001_bib6","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2009.11.001_bib7","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","article-title":"Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry","volume":"30","author":"Eng","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2009.11.001_bib8","unstructured":"United States Food and Drug Administration, Available from http:\/\/www.fda.gov\/search\/replagal."},{"key":"10.1016\/j.ymgme.2009.11.001_bib9","unstructured":"Canadian Expert Drug Advisory Committee, Available from http:\/\/www.cadth.ca\/index.php\/en\/cdr\/searchagalsidase."},{"key":"10.1016\/j.ymgme.2009.11.001_bib10","doi-asserted-by":"crossref","unstructured":"L.A. Clarke, J.T.R. Clarke, S. Sirrs, M.L. West, R.M. Iwanochko, J.R. Wherrett, C.R. Greenberg, A.K.J. Chan, R. Casey, Fabry disease: recommendations for diagnosis, management, and enzyme replacement therapy in Canada (2005), http:\/\/www.garrod.ca\/resources.","DOI":"10.1385\/MN:32:1:043"},{"key":"10.1016\/j.ymgme.2009.11.001_bib11","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/0197-2456(90)90005-M","article-title":"Power and sample size calculations: a review and computer program","volume":"11","author":"Dupont","year":"1990","journal-title":"Controlled Clin. Trials"},{"key":"10.1016\/j.ymgme.2009.11.001_bib12","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/jmg.15.6.428","article-title":"Angiokeratoma corporis diffusum in a single large family in Nova Scotia. (Anderson-Fabry disease)","volume":"15","author":"Spence","year":"1978","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2009.11.001_bib13","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2009.11.001_bib14","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1681\/ASN.2008080870","article-title":"Agalsidase alfa and kidney dysfunction in Fabry disease","volume":"20","author":"West","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2009.11.001_bib15","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: influence of \u03b1-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine"},{"key":"10.1016\/j.ymgme.2009.11.001_bib16","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1681\/ASN.2006121400","article-title":"Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase beta","volume":"18","author":"Tahir","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2009.11.001_bib17","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/BF03401993","article-title":"Twenty novel mutations in the alpha-galactosidase A gene causing Fabry disease","volume":"5","author":"Topaloglu","year":"1999","journal-title":"Mol. Med."},{"key":"10.1016\/j.ymgme.2009.11.001_bib18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1096-7192(02)00012-4","article-title":"Fabry disease: 45 novel mutations in the alpha-galactosidase A gene causing the classical phenotype","volume":"76","author":"Shabbeer","year":"2002","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2009.11.001_bib19","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/humu.1219","article-title":"Fabry disease: 20 novel GLA mutations in 35 families","volume":"18","author":"Blaydon","year":"2001","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2009.11.001_bib20","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ymgme.2007.10.001","article-title":"Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease","volume":"93","author":"Auray-Blais","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2009.11.001_bib21","doi-asserted-by":"crossref","first-page":"S288","DOI":"10.1002\/humu.1380110190","article-title":"Mutation analysis in 11 French patients with Fabry disease","volume":"1","author":"Guffon","year":"1998","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2009.11.001_bib22","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/hmg\/3.10.1795","article-title":"Fabry disease: twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the alpha-galactosidase A gene","volume":"3","author":"Eng","year":"1994","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2009.11.001_bib23","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/humu.9172","article-title":"Molecular analysis in Fabry disease in Spain: fifteen novel GLA mutations and identification of a homozygous female","volume":"22","author":"Rodr\u00edguez-Mar\u00ed","year":"2003","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2009.11.001_bib24","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF03401671","article-title":"Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes","volume":"3","author":"Eng","year":"1997","journal-title":"Mol. Med."},{"key":"10.1016\/j.ymgme.2009.11.001_bib25","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF01913174","article-title":"Two novel mutations in the alpha-galactosidase gene in Japanese classical hemizygotes with Fabry disease","volume":"41","author":"Okumiya","year":"1996","journal-title":"Jpn. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2009.11.001_bib26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00207037","article-title":"Point mutations in the upstream region of the alpha-galactosidase A gene exon 6 in an atypical variant of Fabry disease","volume":"89","author":"Ishii","year":"1992","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ymgme.2009.11.001_bib27","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1023\/A:1012993305223","article-title":"Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes","volume":"24","author":"Whybra","year":"2001","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2009.11.001_bib28","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s100380170088","article-title":"Fabry disease: twenty novel alpha-galactosidase A mutations causing the classical phenotype","volume":"46","author":"Ashley","year":"2001","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2009.11.001_bib29","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF01910542","article-title":"A 3\u2019 splice site consensus sequence mutation in the intron 3 of the alpha-galactosidase A gene in a patient with Fabry disease","volume":"36","author":"Yokoi","year":"1991","journal-title":"Jinrui Idengaku Zasshi"},{"key":"10.1016\/j.ymgme.2009.11.001_bib30","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/hmg\/2.7.1051","article-title":"Mutation analysis in patients with the typical form of Anderson-Fabry disease","volume":"2","author":"Davies","year":"1993","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2009.11.001_bib31","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/hmg\/3.6.1019","article-title":"A nonsense mutation [R220X] in the alpha-galactosidase A gene detected in a female carrier of Fabry disease","volume":"3","author":"Meaney","year":"1994","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2009.11.001_bib32","first-page":"1186","article-title":"Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease","volume":"53","author":"Eng","year":"1993","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2009.11.001_bib33","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/sj.ejhg.5201184","article-title":"Remarkable variability in renal disease in a large Slovenian family with Fabry disease","volume":"12","author":"Verovnik","year":"2004","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2009.11.001_bib34","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/1479-7364-2-5-297","article-title":"Fabry disease: identification of 50 novel alpha-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations","volume":"2","author":"Shabbeer","year":"2006","journal-title":"Hum. Genomics"},{"key":"10.1016\/j.ymgme.2009.11.001_bib35","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/humu.20144","article-title":"Detection of alpha-galactosidase a mutations causing Fabry disease by denaturing high performance liquid chromatography","volume":"25","author":"Shabbeer","year":"2005","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2009.11.001_bib36","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/hmg\/3.3.503","article-title":"Six novel mutations in the alpha-galactosidase A gene in families with Fabry disease","volume":"3","author":"Ploos van Amstel","year":"1994","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2009.11.001_bib37","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/humu.9327","article-title":"Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease","volume":"25","author":"Sch\u00e4fer","year":"2005","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2009.11.001_bib38","unstructured":"R. Dobrovolny, D. Kwan, M. Rudelli, S. Garman, I. Nazarenko, M. Yasuda, R.J. Desnick, Fabry Disease: 11 Novel \u03b1-Galactosidase A Mutations, in: 58th Annual American Society of Human Genetics Meeting, 2008, p. 633\/W."},{"key":"10.1016\/j.ymgme.2009.11.001_bib39","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2362.2004.01424.x","article-title":"Fabry disease: overall effects of aglasidase alfa treatment","volume":"34","author":"Beck","year":"2004","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2009.11.001_bib40","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","article-title":"Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry Outcome Survey","volume":"28","author":"Linhart","year":"2007","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ymgme.2009.11.001_bib41","unstructured":"Shire Human Genetics Therapies Workshop on Fabry disease, Palma de Mallorca October, 2003."},{"issue":"Suppl. 447","key":"10.1016\/j.ymgme.2009.11.001_bib42","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/08035320510028076","article-title":"Natural history of the cerebrovascular complications of Fabry disease","volume":"94","author":"Mehta","year":"2005","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2009.11.001_bib43","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/AJP.0b013e318074c986","article-title":"Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy \u2013 a retrospective analysis from the Fabry Outcome Survey","volume":"23","author":"Hoffmann","year":"2007","journal-title":"Clin. J. Pain."},{"key":"10.1016\/j.ymgme.2009.11.001_bib44","unstructured":"W. Wilcox, C. Wanner, C. Eng, D.P. Germain, A.M. Martins, Fabry RADAR 2007: The Fabry Registry aggregate data annual report, Available from www.fabry.org\/2007_RADAR.pdf."},{"key":"10.1016\/j.ymgme.2009.11.001_bib45","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/ndt\/gfm848","article-title":"Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy","volume":"23","author":"Ortiz","year":"2008","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2009.11.001_bib46","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/STROKEAHA.108.526293","article-title":"Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry","volume":"40","author":"Sims","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.ymgme.2009.11.001_bib47","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol. Dial. Transplant."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719209004831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719209004831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T18:45:30Z","timestamp":1558637130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719209004831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S1096719209004831"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2009.11.001","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}